Heat Biologics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.76 |
Market Cap |
$23.51 M |
Shares Outstanding |
34.07 M |
Public Float |
29.66 M |
Address |
801 Capitola Drive Durham North Carolina 27713 United States |
Employees | - |
Website | http://www.heatbio.com |
Updated | 07/08/2019 |
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. |